In this talk, the speaker will outline some of the challenges and opportunities of medical imaging AI in research and clinical translation, illustrate how a convergence approach will be helping address some of the barriers, and showcase a variety of AI research projects.
In this talk, translational pharmacoinformatics methods will be presented for the drug interaction research. They include literature based drug interaction discovery, drug interaction signal data mining from health record databases, translational drug interaction and pharmacogenetics studies, drug interaction knowledgebase for cancer phase I clinical trials, and target combination discovery for breast cancer chemo or PARP1 inhibitor resistance.
The era of designs for clinical trials using Bayesian principles begins in 1990 with the publication of the Continual Reassessment Method, but until the mid 1990s, with the dissemination of flexible and powerful Markov Chain Monte Carlo software, only very simple models or models using conjugate priors were feasible. Since then, the landscape has changed considerably and now it is possible to design clinical trials that adapt to accumulating data using mathematical mod
Age-related Macular Degeneration (AMD) is a multifactorial irreversible retina disease and the leading cause of blindness in the developed world. Multiple factors including aging, genetics, and smoking are associated with AMD development and its progression.
This talk will present an overview of some the different challenges and opportunities for biomedical informatics we face in our lab. First, I will present some of our clinical translational research in neurodevelopment in infants diagnosed with congenital heart disease, including developing computational models for diagnosis of subtle brain abnormalities and prognostic neurocognitive predictions.
Andrew Beckley's abstract: The development of resistance to some antibiotics may cause pathogens to become sensitive to other antibiotics in a phenomenon known as collateral sensitivity. Alternating between collaterally sensitive antibiotics has been proposed as a means to reverse resistance, yet clinical implementation has not been successful. This could be due to a lack of knowledge about which antibiotic pairs will be successful in the clinic.
This lecture is designed to promote a common and consistent understanding and application of the University of Pittsburgh policies, standards, and processes with regard to Title IX. The training facilitator will address required timeliness all potential responders must adhere to upon becoming aware of sexual violence, sexual harassment, relationship violence, stalking and discrimination.